U.S. Markets closed
  • S&P 500

    4,400.64
    -0.82 (-0.02%)
     
  • Dow 30

    34,930.93
    -127.59 (-0.36%)
     
  • Nasdaq

    14,762.58
    +102.01 (+0.70%)
     
  • Russell 2000

    2,224.96
    +33.12 (+1.51%)
     
  • Crude Oil

    72.37
    +0.72 (+1.00%)
     
  • Gold

    1,806.00
    +6.20 (+0.34%)
     
  • Silver

    25.00
    +0.35 (+1.40%)
     
  • EUR/USD

    1.1851
    +0.0025 (+0.2133%)
     
  • 10-Yr Bond

    1.2610
    +0.0270 (+2.19%)
     
  • Vix

    18.31
    -1.05 (-5.42%)
     
  • GBP/USD

    1.3905
    +0.0026 (+0.1905%)
     
  • USD/JPY

    109.9200
    +0.1530 (+0.1394%)
     
  • BTC-USD

    40,047.29
    +1,583.99 (+4.12%)
     
  • CMC Crypto 200

    938.33
    +8.40 (+0.90%)
     
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study

·1 min read
  • Forma Therapeutics Holdings Inc (NASDAQ: FMTX) has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202, a pyruvate kinase R activator.

  • The 600 mg high-dose cohort featured fewer hemoglobin responders than the 300-mg arm, but FT-4202 showed a similar safety and tolerability profile as the 300 mg cohort, despite the doubling of the dose.

  • Six of the seven patients who received the 300-mg dose of FT-4202 had hemoglobin increases of 1.0 g/dl or greater from baseline.

  • Four of the seven patients taking 600 mg had hemoglobin increases of 1.0 g/dl or greater from baseline.

  • The 600 mg dose fared numerically worse on other endpoints, too, lowering LDH in four patients compared to the six people positively affected by the 300 mg dose.

  • The median change in LDH and reticulocytes, respectively hematologic and hemolytic biomarkers, was also numerically lower at 600 mg.

  • Forma will conduct an open-label extension study giving a 400-mg dose for 12 weeks.

  • Forma is also using a 400-mg dose and a 200-mg dose in its Phase 2/3 clinical trial. The primary endpoints of phase 2/3 are hemoglobin response at Week 24 and vaso-occlusive crisis rate across the 52-week blinded treatment period.

  • Unblinded 600 mg cohort data will be reported at an upcoming medical conference in Summer 2021, in addition to initial results from the ongoing open-label extension.

  • Price Action: FMTX shares are trading 8.1% lower at $23.13 in market hours on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.